Jnj stock forecast the latest JNJ stock forecast suggests

The latest JNJ stock forecast suggests a moderate upside potential, with analysts setting a 12‑month median target around $170, reflecting steady dividend yields near 3%. The stock is trading in a defensive healthcare sector, which tends to perform well during market volatility. In the case of Johnson & Johnson, the consensus sales estimate of $21.38 billion for the current quarter points to a year-over-year change of -13.6%. The $88.38 billion and $90.62 billion estimates for the current and next fiscal years indicate changes of -5% and +2.5%, respectively. While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. The current forward P/E ratio for JNJ sits below the industry median, giving value investors reason to consider long positions. Forecasts suggest this relative undervaluation could narrow if revenue momentum continues.